Home > Insider Trading > Filing (0001209191-22-044021)

Filing Details

Accession Number:: 0001209191-22-044021
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-08-02 21:42:02
Reporting Period:: 2022-07-29

Accepted Time:: 2022-08-02 21:42:02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1786255	Icosavax Inc.	ICVX	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1874371	Douglas Holtzman	C/O Icosavax, Inc. 1930 Boren Ave., Suite 1000 Seattle WA 98101	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-07-29	585	$7.11	303,048	No	4	S	Direct
Common Stock	Disposition	2022-08-01	9,337	$6.64	293,711	No	4	S	Direct
Common Stock	Disposition	2022-08-02	453	$6.70	293,258	No	4	S	Direct
Common Stock	Disposition	2022-02-18	20,000	$0.00	22,440	No	4	G	Indirect	By Stanley Holtzman

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	G	Indirect	By Stanley Holtzman

Footnotes

Represents shares withheld by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover the withholding taxes upon settlement of restricted stock units issued to the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.93 to $7.75. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Also includes the sale of 7,666 shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.38 to $7.17. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.460 to $6.865. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Douglas Holtzman, Ph.D. holds power-of-attorney (POA) over the shares owned by Stanley Holtzman. As POA, Dr. Holtzman holds voting and dispositive control over such shares. Dr. Holtzman disclaims beneficial ownership of the shares over which he has POA except to the extent of any pecuniary interest therein.